Price cuts secure NHS place for MS drugs
NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis after price cuts enabled the cost regulator to endorse their routine use on the NHS.
Read More
Tag: Avonex
NICE proposes restricting MS therapies
Novartis’ Extavia is the only beta interferon being endorsed by the National Institute for Health and Care Excellence as a cost-effective treatment option for multiple sclerosis.
Read More
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
